NASDAQ:VRCA - Verrica Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.29 -1.57 (-9.31 %) (As of 01/26/2020 04:00 PM ET) Add Compare Today's Range$15.06Now: $15.29▼$17.6050-Day Range$13.06MA: $15.22▼$16.8652-Week Range$6.84Now: $15.29▼$18.67Volume123,899 shsAverage Volume59,487 shsMarket Capitalization$394.02 millionP/E RatioN/ADividend YieldN/ABeta4.1 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRCA Previous Symbol CUSIPN/A CIKN/A Webhttp://www.verrica.com/ Phone484-453-3300Debt Debt-to-Equity RatioN/A Current Ratio17.10 Quick Ratio17.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.48 per share Price / Book4.39Profitability EPS (Most Recent Fiscal Year)($1.41) Net Income$-20,650,000.00 Net MarginsN/A Return on Equity-35.11% Return on Assets-33.59%Miscellaneous Employees16 Outstanding Shares25,770,000Market Cap$394.02 million Next Earnings Date3/5/2020 (Estimated) OptionableNot Optionable Receive VRCA News and Ratings via Email Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VRCA Rates by TradingView Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions What is Verrica Pharmaceuticals' stock symbol? Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA." How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc (NASDAQ:VRCA) posted its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.03. View Verrica Pharmaceuticals' Earnings History. When is Verrica Pharmaceuticals' next earnings date? Verrica Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Verrica Pharmaceuticals. What price target have analysts set for VRCA? 1 Wall Street analysts have issued twelve-month price targets for Verrica Pharmaceuticals' stock. Their forecasts range from $24.00 to $24.00. On average, they expect Verrica Pharmaceuticals' share price to reach $24.00 in the next year. This suggests a possible upside of 57.0% from the stock's current price. View Analyst Price Targets for Verrica Pharmaceuticals. What is the consensus analysts' recommendation for Verrica Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verrica Pharmaceuticals. Has Verrica Pharmaceuticals been receiving favorable news coverage? News stories about VRCA stock have been trending extremely negative on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Verrica Pharmaceuticals earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Verrica Pharmaceuticals. Are investors shorting Verrica Pharmaceuticals? Verrica Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 573,300 shares, a decline of 10.7% from the December 15th total of 641,900 shares. Based on an average daily trading volume, of 74,100 shares, the days-to-cover ratio is presently 7.7 days. Currently, 4.7% of the shares of the stock are sold short. View Verrica Pharmaceuticals' Current Options Chain. Who are some of Verrica Pharmaceuticals' key competitors? Some companies that are related to Verrica Pharmaceuticals include Arvinas (ARVN), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Ligand Pharmaceuticals (LGND), Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Theravance Biopharma (TBPH), Innoviva (INVA), Esperion Therapeutics (ESPR), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV) and TG Therapeutics (TGTX). What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include Gilead Sciences (GILD), Aurora Cannabis (ACB), Exxon Mobil (XOM), Foamix Pharmaceuticals (FOMX), Global Blood Therapeutics (GBT), Progenics Pharmaceuticals (PGNX), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Citigroup (C) and Enterprise Products Partners (EPD). Who are Verrica Pharmaceuticals' key executives? Verrica Pharmaceuticals' management team includes the folowing people: Mr. Ted White, Pres, CEO & Director (Age 54)Mr. Chris Degnan, Chief Financial Officer (Age 39)Mr. Joe Bonaccorso, Chief Commercial Officer (Age 55)Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 47)Christopher G. Hayes, Sec. When did Verrica Pharmaceuticals IPO? (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Verrica Pharmaceuticals' stock price today? One share of VRCA stock can currently be purchased for approximately $15.29. How big of a company is Verrica Pharmaceuticals? Verrica Pharmaceuticals has a market capitalization of $394.02 million. The company earns $-20,650,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.View Additional Information About Verrica Pharmaceuticals. What is Verrica Pharmaceuticals' official website? The official website for Verrica Pharmaceuticals is http://www.verrica.com/. How can I contact Verrica Pharmaceuticals? Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected] MarketBeat Community Rating for Verrica Pharmaceuticals (NASDAQ VRCA)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 95 (Vote Outperform)Underperform Votes: 112 (Vote Underperform)Total Votes: 207MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: Certificate of Deposit (CD) For Risk Adverse Investors?
